Om­ni­care to pay $50 mil­lion to re­solve al­le­ga­tions

Modern Healthcare - - LATE NEWS -

Om­ni­care, the largest in­sti­tu­tional phar­macy provider in the U.S., agreed to pay $50 mil­lion to re­solve al­le­ga­tions that some of its phar­ma­cies im­prop­erly dis­pensed con­trolled sub­stances. The set­tle­ment re­solves al­le­ga­tions that Cincin­nati-based Om­ni­care vi­o­lated the Con­trolled Sub­stances Act, the U.S. Jus­tice Depart­ment said in a news re­lease. The gov­ern­ment al­leged the phar­ma­cies rou­tinely dis­pensed con­trolled sub­stances to res­i­dents of long-term-care fa­cil­i­ties with­out a signed or oral pre­scrip­tion from a prac­ti­tioner, dis­pensed con­trolled sub­stances us­ing in­com­plete pre­scrip­tions, and did not prop­erly doc­u­ment par­tially filled pre­scrip­tions. “These prac­tices are all­too-preva­lent in the long-term-care in­dus­try and are a vi­o­la­tion of fed­eral law,” Steven Det­tel­bach, U.S. at­tor­ney for the North­ern Dis­trict of Ohio, said in a news re­lease. Om­ni­care ad­mit­ted no wrong­do­ing, ac­cord­ing to the set­tle­ment. Om­ni­care said in a news re­lease that the set­tle­ment con­tains no al­le­ga­tions or find­ings that con­trolled sub­stances were un­law­fully di­verted or pa­tients were harmed. “We be­lieve this set­tle­ment pro­vides long-term-care phar­ma­cies, long-term-care fa­cil­i­ties and pre­scribers with clear di­rec­tion re­gard­ing the pro­ce­dures that must be fol­lowed when dis­pens­ing con­trolled sub­stances,” Om­ni­care CEO John Figueroa said in the re­lease.

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.